Aerie Pharmaceuticals posted a loss of $97.316 million under GAAP for 6 months of 2020, up 2.3% from a loss of $95.115 million the previous year. Revenue increased by 43.8% to $38,374 million compared to $26,687 million a year earlier.
Aerie Pharmaceuticals posted a loss of $97.316 million under GAAP for 6 months of 2020, up 2.3% from a loss of $95.115 million the previous year. Revenue increased by 43.8% to $38,374 million compared to $26,687 million a year earlier. 
investors.aeriepharma.com
English (US) 